White House Urges RSV Shot Manufacturers to Meet High Demand

Beyfortus, a key drug in preventing RSV in infants, faces shortage due to unanticipated demand.

Senior Biden administration officials met with manufacturers of the RSV shot, urging them to meet the high demand ahead of the winter months.
The drug, marketed as Beyfortus, is currently in short supply due to manufacturers not anticipating the immense demand.
Beyfortus is one of two available treatments in the U.S. that can protect infants from RSV, reducing the risk of hospitalizations by about 80 percent.
The CDC has expedited the release of 77,000 additional doses, but this is not expected to be enough to alleviate the shortage.
RSV cases in the U.S. began a sharp upward trend in the middle of October, with at least 7,557 cases detected.